EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access

Transdermal 17β-Estradiol for the Treatment of COVID-19: Protocol of an Early Terminated Phase 2 Randomized Controlled Trial

Adel Ganaw iD, Kayleigh Griffiths iD, Moad Ehfeda iD, Ashraf Elmalik iD, Manoj Varghese iD, Muna Al Maslamani iD, Prem Chandra iD, Hugh Montgomery iD, Melanie Madhani iD

JMIR Research Protocols · 11.09.2026 · 15 · e81541-e81541

DOI: 10.2196/81541 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JMIR Research Protocols, online erschienen am 11.09.2026. Verfasst von Adel Ganaw und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hamad Medical Corporation, Doha, Qatar. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Estradiol, Estrogens. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early epidemiological studies suggested that pre- and postmenopausal women receiving estrogen therapy were less likely to develop severe disease or die from COVID-19 infection. Potential mechanisms include estrogen-mediated immunomodulation and 17β-estradiol–induced downregulation of angiotensin-converting enzyme type 2 (ACE2), the cellular receptor for SARS-CoV-2.

Objective

This study aimed to evaluate the feasibility, safety, and preliminary efficacy of transdermal 17β-estradiol as an adjunctive treatment for COVID-19 in men and postmenopausal women.

Methods

We designed and conducted a randomized controlled trial comparing 17β-estradiol transdermal gel plus standard care with standard care alone in adults with confirmed COVID-19. Initial ethics and funding approvals were obtained in March 2021. Owing to changes in the epidemiology of COVID-19 in Qatar and revisions to national quarantine policies, protocol amendments were required before recruitment commenced in February 2022. The treatment duration was reduced from 10 to 7 days due to changes in national quarantine guidelines. Recruitment and follow-up were conducted between February 2022 and June 2022.

Results

Recruitment was substantially lower than anticipated because widespread COVID-19 vaccination, declining disease severity, and revised national quarantine policies markedly reduced the number of eligible hospitalized patients. Consequently, the planned sample size was not achieved, and the study was terminated in June 2022. A total of 29 men with mild COVID-19 were enrolled, with 44.8% (n=13) randomized to standard care and 55.2% (n=16) to transdermal 17β-estradiol plus standard care. The intervention was well tolerated, with no adverse safety signals or thromboembolic events reported.

Conclusions

Although the study was underpowered to assess efficacy because recruitment targets were not achieved, it showed that transdermal 17β-estradiol was well tolerated, with no major safety concerns among enrolled participants. The experience also provided important operational lessons for conducting clinical trials during rapidly evolving pandemics. Adequately powered studies are required to determine whether transdermal estrogen has therapeutic potential against COVID-19, other ACE2-mediated coronavirus infections, or potentially other severe viral illnesses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentEstradiolEstrogensAdultAgedFemaleHumansMaleMiddle AgedAdministration, CutaneousCOVID-19Early Termination of Clinical TrialsSARS-CoV-2Randomized Controlled Trials as TopicClinical Trials, Phase II as Topic

Stichwörter der Autor:innen

17β-estradiolCOVID-19SARS-CoV-2estrogenfeasibilityimmunomodulationpostmenopausalsafety

Substanzen

EstradiolEstrogens

Autor:innen und Institutionen

  • Hamad Medical Corporation, Doha, Qatar.
  • Cardiovascular Department, University of Birmingham, Edgbaston, Selly Oak, Birmingham, B15 2TT, United Kingdom, +44 (0)121 414 3344.
  • Department of Medicine, University College London, London, United Kingdom.

ORCID-Profile: Adel Ganaw, Kayleigh Griffiths, Moad Ehfeda, Ashraf Elmalik, Manoj Varghese, Muna Al Maslamani, Prem Chandra, Hugh Montgomery, Melanie Madhani

Förderung

  • Wellcome Trust

Zitieren

APA

Ganaw, A., Griffiths, K., Ehfeda, M., Elmalik, A., Varghese, M., Al Maslamani, M., Chandra, P., Montgomery, H., & Madhani, M. (2026). Transdermal 17β-Estradiol for the Treatment of COVID-19: Protocol of an Early Terminated Phase 2 Randomized Controlled Trial. JMIR Research Protocols, 15, e81541-e81541. https://doi.org/10.2196/81541

Vancouver

Ganaw A, Griffiths K, Ehfeda M, Elmalik A, Varghese M, Al Maslamani M, et al. Transdermal 17β-Estradiol for the Treatment of COVID-19: Protocol of an Early Terminated Phase 2 Randomized Controlled Trial. JMIR Research Protocols. 2026;15:e81541-e81541. doi:10.2196/81541

BibTeX
@article{Ganaw2026,
  author = {Ganaw, Adel and Griffiths, Kayleigh and Ehfeda, Moad and Elmalik, Ashraf and Varghese, Manoj and Al Maslamani, Muna and Chandra, Prem and Montgomery, Hugh and Madhani, Melanie},
  title = {Transdermal 17β-Estradiol for the Treatment of COVID-19: Protocol of an Early Terminated Phase 2 Randomized Controlled Trial},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e81541--e81541},
  doi = {10.2196/81541}
}
Kostenlos starten →